These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19625653)

  • 21. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
    Poehlein CH; Hu HM; Yamada J; Assmann I; Alvord WG; Urba WJ; Fox BA
    J Immunol; 2003 Feb; 170(4):2004-13. PubMed ID: 12574370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T; Lemoi BA; Sentman CL
    Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive immunity and enhanced CD8+ T cell response to Listeria monocytogenes in the absence of perforin and IFN-gamma.
    Badovinac VP; Harty JT
    J Immunol; 2000 Jun; 164(12):6444-52. PubMed ID: 10843700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes.
    Boissonnas A; Scholer-Dahirel A; Simon-Blancal V; Pace L; Valet F; Kissenpfennig A; Sparwasser T; Malissen B; Fetler L; Amigorena S
    Immunity; 2010 Feb; 32(2):266-78. PubMed ID: 20137985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perforin-deficient CD8+ T cells: in vivo priming and antigen-specific immunity against Listeria monocytogenes.
    White DW; MacNeil A; Busch DH; Pilip IM; Pamer EG; Harty JT
    J Immunol; 1999 Jan; 162(2):980-8. PubMed ID: 9916723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin.
    He W; Hao J; Dong S; Gao Y; Tao J; Chi H; Flavell R; O'Brien RL; Born WK; Craft J; Han J; Wang P; Zhao L; Wu J; Yin Z
    J Immunol; 2010 Jul; 185(1):126-33. PubMed ID: 20525896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
    Baxevanis CN; Gritzapis AD; Papamichail M
    J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo.
    Prévost-Blondel A; Roth E; Rosenthal FM; Pircher H
    J Immunol; 2000 Apr; 164(7):3645-51. PubMed ID: 10725721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of CD28 within CD4
    Escarra-Senmarti M; Bueno-Topete MR; Jave-Suarez LF; Gomez-Bañuelos E; Gutierrez-Franco J; Vega-Magaña N; Aguilar-Lemarroy A; Pereira-Suarez AL; Haramati J; Del Toro-Arreola S
    Immunol Lett; 2017 Feb; 182():30-38. PubMed ID: 28087292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
    Spear P; Barber A; Sentman CL
    Oncoimmunology; 2013 Apr; 2(4):e23564. PubMed ID: 23734311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal 3 availability limits the CD8 T cell response to a solid tumor.
    Curtsinger JM; Gerner MY; Lins DC; Mescher MF
    J Immunol; 2007 Jun; 178(11):6752-60. PubMed ID: 17513722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96.
    Strbo N; Oizumi S; Sotosek-Tokmadzic V; Podack ER
    Immunity; 2003 Mar; 18(3):381-90. PubMed ID: 12648455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
    Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
    J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
    Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
    J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
    Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
    J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
    Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
    J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.